Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies

Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2

(2022) Pengcheng Han et al.   CELL

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

(2022) Elisabetta Cameroni et al.   NATURE

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

(2022) Laura A. VanBlargan et al.   NATURE MEDICINE

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans

(2022) Yueh-Ming Loo et al.   Science Translational Medicine

Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction

(2022) Shijulal Nelson-Sathi et al.   BMC Molecular and Cell Biology

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

(2022) Emi Takashita et al.   NEW ENGLAND JOURNAL OF MEDICINE

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

(2022) Kathryn Westendorf et al.   Cell Reports

Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants

(2022) Wan-Ling Wu et al.   JCI Insight

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

(2022) Aekkachai Tuekprakhon et al.   CELL

The recently emerged BA.4 and BA.5 lineages of Omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic – Correspondence

(2022) Ranjan K. Mohapatra et al.   International Journal of Surgery

Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape

(2021) Zhiqiang Ku et al.   Nature Communications

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

(2021) Cheolmin Kim et al.   Nature Communications

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

(2021) Emma S. Winkler et al.   CELL

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

(2021) Naveenchandra Suryadevara et al.   CELL

Structural basis for the different states of the spike protein of SARS-CoV-2 in complex with ACE2

(2021) Renhong Yan et al.   CELL RESEARCH

FDA approves 100th monoclonal antibody product

(2021) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

(2021) Bryan E. Jones et al.   Science Translational Medicine

Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients

(2021) Qihong Yan et al.   Emerging Microbes & Infections

Tackling COVID-19 with neutralizing monoclonal antibodies

(2021) Davide Corti et al.   CELL

Neutralizing antibodies for the prevention and treatment of COVID-19

(2021) Lanying Du et al.   Cellular & Molecular Immunology

An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future

(2021) Marco Tuccori et al.   Expert Opinion on Drug Discovery

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

(2021) Rita E. Chen et al.   NATURE

Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function

(2021) Tzu-Jing Yang et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

(2021) Conrad E. Z. Chan et al.   PLoS One

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

(2021) Lingshu Wang et al.   SCIENCE

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

(2021) Jinhui Dong et al.   Nature Microbiology

Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells

(2021) Jeong Hyun Lee et al.   npj Vaccines

Development and Evaluation of a Set of Spike and Receptor Binding Domain-Based Enzyme-Linked Immunosorbent Assays for SARS-CoV-2 Serological Testing

(2021) Rosa Camacho-Sandoval et al.   Diagnostics

The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2

(2021) Dong-Kyun Ryu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains

(2021) Peter Radvak et al.   Nature Communications

Identification of a novel SARS-CoV-2 P.1 sub-lineage in Brazil provides new insights about the mechanisms of emergence of variants of concern

(2021) Tiago Gräf et al.   Virus Evolution

Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies

(2021) Jun-biao Xue et al.   Current Medical Science

Coronavirus Infections—More Than Just the Common Cold

(2020) Catharine I. Paules et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

(2020) Daniel Wrapp et al.   SCIENCE

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

(2020) Rui Shi et al.   NATURE

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

(2020) Dora Pinto et al.   NATURE

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

(2020) Jun Lan et al.   NATURE

Structural basis of receptor recognition by SARS-CoV-2

(2020) Jian Shang et al.   NATURE

A serological assay to detect SARS-CoV-2 seroconversion in humans

(2020) Fatima Amanat et al.   NATURE MEDICINE

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

(2020) Yuan Huang et al.   ACTA PHARMACOLOGICA SINICA

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

(2020) Christopher O. Barnes et al.   CELL

The molecular virology of Coronaviruses

(2020) Ella Hartenian et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

(2020) Davide F. Robbiani et al.   NATURE

Potently neutralizing and protective human antibodies against SARS-CoV-2

(2020) Seth J. Zost et al.   NATURE

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

(2020) Seth J. Zost et al.   NATURE MEDICINE

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

(2020) Johanna Hansen et al.   SCIENCE

Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2

(2020) Alex Renn et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

(2020) Ahmad Abu Turab Naqvi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

(2020) Christopher O. Barnes et al.   NATURE

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

(2020) David M. Weinreich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be

(2020) Giuseppina Mariano et al.   Frontiers in Molecular Biosciences

Five computational developability guidelines for therapeutic antibody profiling

(2019) Matthew I. J. Raybould et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy

(2018) Juan C. Almagro et al.   Frontiers in Immunology

Monoclonal antibodies for the treatment of Ebola virus disease

(2016) A. L. Moekotte et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans

(2016) Raffael Nachbagauer et al.   mBio

IgG Subclasses and Allotypes: From Structure to Effector Functions

(2014) Gestur Vidarsson et al.   Frontiers in Immunology

Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain

(2012) Juan Carlos Almagro et al.   JOURNAL OF MOLECULAR RECOGNITION

Natural and man-made V-gene repertoires for antibody discovery

(2012) William J. J. Finlay et al.   Frontiers in Immunology

High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations

(2010) Y.-C. Wu et al.   BLOOD

Enhanced antibody half-life improves in vivo activity

(2010) Jonathan Zalevsky et al.   NATURE BIOTECHNOLOGY

Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire

(2009) J. Glanville et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA